Ajai Chari MD

Hematologic Oncology

Professor of Clinical Medicine, UCSF Director Multiple Myeloma Program

1 Gustave L Levy Pl# 1185New York, NY 10029
Phone+1 212-241-7873
Fax+1 212-241-3908

Dr. Chari is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chari's full profile Already have an account?

Education & Training

SUNY Upstate Medical UniversityResidency, Gastroenterology, 2021 - 2027
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2002 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
David Geffen School of Medicine at UCLAClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
CA State Medical License 2023 - 2027
NY State Medical License 2000 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Super Doctor SuperDoctors.com

Clinical Trials

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
UNKNOWN
PHASE1, PHASE2
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
COMPLETED
PHASE2
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
COMPLETED
PHASE2

Publications & Presentations

PubMed

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.
Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C Minnema, Niels van de Donk
Blood. 2026-08-06
Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model.
Jodi Lipof, Brian Bloudek, Avik Ray, Jie Ting, Ken Hasegawa
Clinical Lymphoma, Myeloma & Leukemia. 2026-08-01
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.
Nizar Bahlis, Thierry Facon, Jesus San-Miguel, Saad Z Usmani, Meletios A Dimopoulos
Blood Advances. 2026-07-14

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple MyelomaJune 2016

Press Mentions

ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the FieldJuly 25th, 2026
New Standard of Care in Relapsed Multiple Myeloma? Teclistamab Improves SurvivalJune 2nd, 2026
Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MDJanuary 31st, 2023